{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:53:05Z","timestamp":1790146385073,"version":"4.0.1"},"reference-count":40,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,11,16]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>The addition of rituximab to corticosteroid and CsA is safe and effective for first-line treatment of cGVHD. Resistance of PD-L1hi B cells to anti-CD20 depletion may lead to the suppression of activated Tfh cells and cGVHD control.<\/jats:p>","DOI":"10.1182\/blood-2017-05-786137","type":"journal-article","created":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T20:50:15Z","timestamp":1504299015000},"page":"2186-2195","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":39,"title":["Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study"],"prefix":"10.1182","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3474-0002","authenticated-orcid":false,"given":"Florent","family":"Malard","sequence":"first","affiliation":[{"name":"Centre de Recherche en Transplantation et Immunologie Unit\u00e9 Mixte de Recherche 1064, INSERM, Universit\u00e9 de Nantes, Nantes, France;"},{"name":"Sorbonne Universit\u00e9s, Universit\u00e9 Pierre et Marie Curie Universit\u00e9 Paris 06, INSERM, Centre de Recherche Saint-Antoine, Paris, France;"},{"name":"Service d'H\u00e9matologie Clinique et de Th\u00e9rapie Cellulaire, Assistance Publique-H\u00f4pitaux de Paris, H\u00f4pital, Saint Antoine, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Labopin","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie Clinique et de Th\u00e9rapie Cellulaire, Assistance Publique-H\u00f4pitaux de Paris, H\u00f4pital, Saint Antoine, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[{"name":"Service des Maladies du Sang, Centre Hospitalo-Universitaire de Lille, Lille, France;"},{"name":"Centre de Recherche sur L'inflammation de Lille, INSERM U995, Universit\u00e9 Lille 2, Lille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Chantepie","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie Clinique, Centre Hospitalo-Universitaire de Caen, Caen, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Guillaume","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie Clinique, Centre Hospitalo-Universitaire de Nantes, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[{"name":"Institut Paoli-Calmettes, Universit\u00e9 d'Aix-Marseille, Centre National de la Recherche Scientifique, INSERM, Centre de Recherche en Canc\u00e9rologie de Marseille, Marseille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Tabrizi","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie Clinique, Centre Hospitalo-Universitaire de Bordeaux, Bordeaux, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Magro","sequence":"additional","affiliation":[{"name":"Service des Maladies du Sang, Centre Hospitalo-Universitaire de Lille, Lille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Vanhove","sequence":"additional","affiliation":[{"name":"Centre de Recherche en Transplantation et Immunologie Unit\u00e9 Mixte de Recherche 1064, INSERM, Universit\u00e9 de Nantes, Nantes, France;"},{"name":"Institut de Transplantation Urologie N\u00e9phrologie and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Blancho","sequence":"additional","affiliation":[{"name":"Centre de Recherche en Transplantation et Immunologie Unit\u00e9 Mixte de Recherche 1064, INSERM, Universit\u00e9 de Nantes, Nantes, France;"},{"name":"Institut de Transplantation Urologie N\u00e9phrologie and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie Clinique, Centre Hospitalo-Universitaire de Nantes, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Gaugler","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9s, Universit\u00e9 Pierre et Marie Curie Universit\u00e9 Paris 06, INSERM, Centre de Recherche Saint-Antoine, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Chevallier","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie Clinique, Centre Hospitalo-Universitaire de Nantes, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9s, Universit\u00e9 Pierre et Marie Curie Universit\u00e9 Paris 06, INSERM, Centre de Recherche Saint-Antoine, Paris, France;"},{"name":"Service d'H\u00e9matologie Clinique et de Th\u00e9rapie Cellulaire, Assistance Publique-H\u00f4pitaux de Paris, H\u00f4pital, Saint Antoine, Paris, France;"},{"name":"Service d'H\u00e9matologie Clinique, Centre Hospitalo-Universitaire de Nantes, Nantes, France;"},{"name":"Centre d'Investigation Clinique en Canc\u00e9rologie Centre Hospitalo-Universitaire de Nantes, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"22","key":"2019111611510097700_B1","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced mortality after allogeneic hematopoietic-cell transplantation","volume":"363","author":"Gooley","year":"2010","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111611510097700_B2","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.bbmt.2014.04.021","article-title":"Continuous reduced nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a single-institution\u2019s three decade experience","volume":"20","author":"Malard","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2019111611510097700_B3","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.bbmt.2014.10.021","article-title":"Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research","volume":"21","author":"Arai","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2019111611510097700_B4","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.bbmt.2010.06.015","article-title":"Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD","volume":"16","author":"Wolff","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2019111611510097700_B5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1053\/bbmt.2001.v7.pm11400948","article-title":"Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease","volume":"7","author":"Arora","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"issue":"21","key":"2019111611510097700_B6","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1182\/blood-2009-02-202937","article-title":"Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease","volume":"113","author":"Martin","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2019111611510097700_B7","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood.V100.1.48","article-title":"Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone","volume":"100","author":"Koc","year":"2002","journal-title":"Blood"},{"issue":"12","key":"2019111611510097700_B8","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1182\/blood-2004-01-0200","article-title":"Duration of immunosuppressive treatment for chronic graft-versus-host disease","volume":"104","author":"Stewart","year":"2004","journal-title":"Blood"},{"issue":"4","key":"2019111611510097700_B9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/bbmt.2003.50026","article-title":"Chronic graft-versus-host disease","volume":"9","author":"Lee","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2019111611510097700_B10","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2014-12-567834","article-title":"Aberrant B-cell homeostasis in chronic GVHD","volume":"125","author":"Sarantopoulos","year":"2015","journal-title":"Blood"},{"issue":"20","key":"2019111611510097700_B11","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1158\/1078-0432.CCR-07-1290","article-title":"High levels of B-cell activating factor in patients with active chronic graft-versus-host disease","volume":"13","author":"Sarantopoulos","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"16","key":"2019111611510097700_B12","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2008-09-177840","article-title":"Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease","volume":"113","author":"Sarantopoulos","year":"2009","journal-title":"Blood"},{"issue":"7","key":"2019111611510097700_B13","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1182\/blood-2004-09-3660","article-title":"Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission","volume":"105","author":"Miklos","year":"2005","journal-title":"Blood"},{"issue":"3","key":"2019111611510097700_B14","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1046\/j.1365-2141.2003.04446.x","article-title":"Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin\u2019s lymphoma","volume":"122","author":"Shimoni","year":"2003","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111611510097700_B15","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood-2006-01-0233","article-title":"Rituximab for steroid-refractory chronic graft-versus-host disease","volume":"108","author":"Cutler","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2019111611510097700_B16","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/sj.leu.2403996","article-title":"Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease","volume":"20","author":"Okamoto","year":"2006","journal-title":"Leukemia"},{"issue":"3","key":"2019111611510097700_B17","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/sj.bmt.1705725","article-title":"Treatment of refractory chronic GVHD with rituximab: a GITMO study","volume":"40","author":"Zaja","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2019111611510097700_B18","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/bmt.2008.12","article-title":"Rituximab as salvage therapy for refractory chronic GVHD","volume":"41","author":"Mohty","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2019111611510097700_B19","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/bmt.2012.203","article-title":"Safety and efficacy of rituximab in steroid-refractory chronic GVHD","volume":"48","author":"Clavert","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"25","key":"2019111611510097700_B20","doi-asserted-by":"crossref","first-page":"6145","DOI":"10.1182\/blood-2011-12-395970","article-title":"Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence","volume":"119","author":"Arai","year":"2012","journal-title":"Blood"},{"issue":"8","key":"2019111611510097700_B21","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1182\/blood-2013-04-495895","article-title":"Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial","volume":"122","author":"Cutler","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2019111611510097700_B22","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.bbmt.2015.04.023","article-title":"Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab","volume":"21","author":"Solomon","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2019111611510097700_B23","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2019111611510097700_B24","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.bbmt.2015.02.025","article-title":"Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report","volume":"21","author":"Lee","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2019111611510097700_B25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"2019111611510097700_B26","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1053\/bbmt.2002.v8.pm12234170","article-title":"Development and validation of a scale to measure symptoms of chronic graft-versus-host disease","volume":"8","author":"Lee","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111611510097700_B27","doi-asserted-by":"crossref","first-page":"5997","DOI":"10.1038\/ncomms6997","article-title":"PD-L1hi B cells are critical regulators of humoral immunity","volume":"6","author":"Khan","year":"2015","journal-title":"Nat Commun"},{"issue":"6","key":"2019111611510097700_B28","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1182\/blood-2013-11-539031","article-title":"Bone marrow T-cell infiltration during acute GVHD is associated with delayed B-cell recovery and function after HSCT","volume":"124","author":"Mensen","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2019111611510097700_B29","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2014-03-563544","article-title":"Failure-free survival after initial systemic treatment of chronic graft-versus-host disease","volume":"124","author":"Inamoto","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2019111611510097700_B30","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1182\/blood.V96.12.3995","article-title":"Thalidomide for treatment of patients with chronic graft-versus-host disease","volume":"96","author":"Koc","year":"2000","journal-title":"Blood"},{"issue":"1","key":"2019111611510097700_B31","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bbmt.2011.05.016","article-title":"Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a Children\u2019s Oncology Group study","volume":"18","author":"Gilman","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"20","key":"2019111611510097700_B32","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project","volume":"113","author":"Carson","year":"2009","journal-title":"Blood"},{"key":"2019111611510097700_B33","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ctrv.2016.11.015","article-title":"Rituximab: 13 open questions after 20years of clinical use","volume":"53","author":"Pavanello","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"2019111611510097700_B34","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1182\/blood-2010-10-307819","article-title":"Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease","volume":"117","author":"Sarantopoulos","year":"2011","journal-title":"Blood"},{"issue":"11","key":"2019111611510097700_B35","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1182\/blood-2014-09-599159","article-title":"CD24(hi)CD27+ and plasmablast-like regulatory B cells in human chronic graft-versus-host disease","volume":"125","author":"de Masson","year":"2015","journal-title":"Blood"},{"issue":"13","key":"2019111611510097700_B36","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1182\/blood-2014-04-571125","article-title":"Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD","volume":"124","author":"Khoder","year":"2014","journal-title":"Blood"},{"issue":"10","key":"2019111611510097700_B37","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/intimm\/dxv038","article-title":"The expanding family of regulatory B cells","volume":"27","author":"Mauri","year":"2015","journal-title":"Int Immunol"},{"issue":"4","key":"2019111611510097700_B38","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.immuni.2015.04.005","article-title":"Regulatory B cells: origin, phenotype, and function","volume":"42","author":"Rosser","year":"2015","journal-title":"Immunity"},{"issue":"25","key":"2019111611510097700_B39","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1182\/blood-2014-03-562231","article-title":"Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans","volume":"123","author":"Flynn","year":"2014","journal-title":"Blood"},{"issue":"20","key":"2019111611510097700_B40","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2015-12-688895","article-title":"Circulating T follicular helper cells with increased function during chronic graft-versus-host disease","volume":"127","author":"Forcade","year":"2016","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/20\/2186\/1403433\/blood786137.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/20\/2186\/1403433\/blood786137.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T11:51:17Z","timestamp":1573905077000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/130\/20\/2186\/115021\/Rituximabbased-firstline-treatment-of-cGVHD-after"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,16]]},"references-count":40,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2017,11,16]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-05-786137","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,16]]}}}